Clinical trials: Neoplasms, Germ Cell and Embryonal
Recurrent Melanoma, Stage IIA Melanoma
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
This phase II trial is studying how well saracatinib works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma
- Trial name
- NCT00669019
- Testing
- saracatinib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
Background: Melanoma antigen recognized by T cells (MART-1) is a gene that is present in melanoma cells. This study tests an experimental treatment that uses the patient's own lymphocytes (type of white blood cell), which are…
- Trial name
- NCT00706992
- Testing
- ALVAC-MART-1 vaccine, MART-1:26-35(27L) peptide vaccine, Aldesleukin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Burkitt Lymphoma, Retinoblastoma
Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment
Digital case management systems have the potential to increase compliance with protocol-driven treatment, reduce treatment abandonment and ultimately help to close the discrepancy in pediatric cancer outcomes between Low and…
- Conditions
- Burkitt Lymphoma, Retinoblastoma, Diffuse Large B-cell Lymphoma
- Trial name
- NCT03677128
- Testing
- mNavigator
- Where
- Tanzania
- Volunteers
- 75 people
- Sponsor
- Duke University
Glioblastoma Multiforme
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
The purpose of this study is to evaluate the objective response rate and 6-month progression-free survival rate of XL184 in subjects with recurrent or progressive glioblastoma multiforme.
- Trial name
- NCT00704288
- Testing
- XL184
- Where
- 8 sites in United States
- Volunteers
- 222 people
- Sponsor
- Exelixis
Neuroendocrine Tumors, Carcinoid Tumors
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied.
- Trial name
- NCT01253161
- Testing
- Pasireotide Long Acting Release (LAR)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Adult Giant Cell Glioblastoma, Adult Glioblastoma
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
NovoTTF-100A is a device and Bevacizumab is a study drug that have both been approved by the FDA (Food and Drug Administration) for use as monotherapy in treating glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01894061
- Testing
- Bevacizumab, NovoTTF-l00A, Quality of Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
Glioma
The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast enhancement and T2 FLAIR on MRI. Investigators then plan to compare patterns of failure with target volumes, pre-treatment MRI changes and…
- Trial name
- NCT03242824
- Testing
- Fluorine F 18 Fluorodopa, Intensity-Modulated Radiation Therapy, Positron Emission Tomography
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
Glioblastoma, Glioma
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
The purpose of this surveillance is to evaluate the postmarketing safety and efficacy of Temodal capsule (temozolomide) under actual conditions of use, and to understand some of the following points that are in question and…
- Conditions
- Glioblastoma, Glioma, Astrocytoma
- Trial name
- NCT00723827
- Testing
- Temozolomide, Radiotherapy
- Volunteers
- 682 people
- Sponsor
- Merck Sharp & Dohme LLC
Neuroblastoma, Sarcoma
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
The purpose of this study is to find out what effects, good and/or bad treatment with a new combination of drugs, cyclophosphamide, topotecan, and bevacizumab has on the patient and their cancer.
- Trial name
- NCT01492673
- Testing
- Cyclophosphamide, Topotecan, and Bevacizumab
- Where
- 7 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumors
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works.
- Trial name
- NCT04704154
- Testing
- Regorafenib, (Stivarga, BAY73-4506), Nivolumab (Opdivo)
- Where
- 34 sites in United States, Belgium and 6 more
- Volunteers
- 175 people
- Sponsor
- Bayer
Solid Tumors
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with…
- Trial name
- NCT03347123
- Testing
- Epacadostat, Nivolumab, Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Incyte Corporation
Melanoma
Trametinib With GSK2141795 in BRAF Wild-type Melanoma
This is a multicenter phase II clinical study of trametinib in combination with GSK2141795 in patients with BRAF wild-type mutation melanoma.
- Trial name
- NCT01941927
- Testing
- Trametinib (GSK1120212), GSK2141795
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Adil Daud
Spinal Tumor
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
The goal of the first part of this clinical research study is to learn how to deliver more accurate radiation treatment of tumors in the spine.
- Trial name
- NCT01624220
- Testing
- Spinal SBRT (Standard Dose), Spinal SBRT (Higher Dose), Gold Seed Implantation
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first…
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT04514497
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 23 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00354913
- Testing
- hydroxyurea, imatinib mesylate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00998010
- Testing
- bortezomib + temozolomide+ radiation therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain Metastases, Adult
Neoadjuvant Immunotherapy in Brain Metastases
The purpose of this phase 2 study is to assess the feasibility and efficacy of neoadjuvant immunotherapy in patients with previously untreated, surgically-resectable, solid tumor brain metastases.
- Trial name
- NCT04434560
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sarah Sammons, MD
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase I/II trial to study the effectiveness of erlotinib in treating patients who have recurrent malignant glioma or recurrent or progressive meningioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT00045110
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
This phase II trial studies how well dovitinib works in treating patients with recurrent or progressive glioblastoma. Dovitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT01753713
- Testing
- dovitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Manmeet Ahluwalia, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.